Diabetes : Adocia’s technology backed again (at a higher price) by Lilly – read
This morning Adocia and Lilly announced that they had renewed their partnership to develop BioChaperone Lispro, an ultra-fast acting insulin based on Lilly’s short-acting insulin lispro (Humalog) and Adocia’s technology. The product should compete with Novo-Nordisk’s NN1218 which entered phase III in 2014 and should be filed with the regulatory authorities late in 2015. Phase II data are very compelling. Adocia will receive an upfront payment of USD50m, up to USD520m in milestones and tiered royalties on sales. Interestingly the company has other interesting assets that could be available for partnerships in the coming months. Other companies in the field of Diabetes could be well inspired to have a close look to what Adocia is doing.
For more information, please contact firstname.lastname@example.org